Ulcerative colitis alleviation of colon-specific delivered rhamnolipid/fullerene nanocomposites via dual modulation in oxidative stress and intestinal microbiome

Ulcerative colitis inflammation is profoundly alleviated by colon-targeting delivery of low dose (0.4 mg kg −1 ) rhamnolipid/fullerene nanocomposites via the synergism of oxidative stress mitigation and gut microbiome recovery.